Arina KOZLOVA - CMFA - Design, Synthesis and Evaluation of Original 1-H-indol-3-yl Heterocyclic Derivatives as Tryptophan 2,3-Dioxygenase Inhibitors

Bruxelles Woluwe

September 01, 2021

September 1st, 2021, 5pm, Auditoire central Maisin

Arina KOZLOVA

Medicinal Chemistry (CMFA)

Design, Synthesis and Evaluation of Original 1-H-indol-3-yl Heterocyclic Derivatives as Tryptophan 2,3-Dioxygenase Inhibitors 

Director : Raphaël Frédérick, co-director : Benoît Van den Eynde.

Related publications :

  • Kozlova A, Frédérick R. Current State on Tryptophan 2,3-Dioxygenase Inhibitors: A Patent Review. Expert Opin. Ther. Pat. 2019, 29 (1), 11–23. doi: 10.1080/13543776.2019.1556638
  • Kozlova A, Thabault L, Liberelle M, Klaessens S, Prévost JRC, Mathieu C, Pilotte L, Stroobant V, Van den Eynde B, Frédérick R. Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-Dioxygenase. J Med Chem. 2021 Aug 2. doi: 10.1021/acs.jmedchem.1c00323.
  • Kozlova A, Thabault L, Dauguet N, Stroobant V, Pilotte L, Liberelle M, Van den Eynde B, Frédérick R. Investigation of chalcogen bioisosteric replacement in a series of heterocyclic inhibitors of tryptophan 2,3-dioxygenase. Eur J Med Chem 2021. Under revision.

Info: raphael.frederick@uclouvain.be